THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 2, 2007--Amgen (NASDAQ:AMGN) today posted to its corporate Web site comments in response to the Center for Medicare and Medicaid Services' (CMS) Proposed Decision Memorandum (PDM) for Erythropoiesis Stimulating Agents (ESAs) for Non-Renal Disease Indications released on May 14, 2007. CMS has stated that a public comment period on the proposed National Coverage Determination (NCD) will end on June 13, 2007 with a final policy expected to be released within 60 days.
In its detailed submission to the proposed NCD, Amgen reinforced its commitment to the highest standards of patient safety and to working with CMS to ensure that coverage decisions are consistent with the available science and in the best interest of patients.
Amgen's complete submission and executive summary have been posted on the company's Web site, www.amgen.com. Go to http://wwwext.amgen.com/media/amgen_cms_response.html.
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks and Washington, DC
Trish Hawkins, 805-447-5631 (media)
Kelley Davenport, 202-585-9637 (media)
Arvind Sood, 805-447-1060 (investors)